Submitted by: Edmond Sandouk

Overview

Dry eye disease (DED) is a multifactorial disorder of theocular surface, in which inflammation is a central component of both symptoms and pathogenesis[1].

While vitamin D is recognized for its role in calcium regulation and bone health, it also has immunomodulatory and anti-inflammatory properties that may benefit ocular health[2].

Multiple studies have investigated the impact of systemic vitamin D supplementation on DED. Notably, Bae et al. conducted a randomized controlled trial on patients with DED and vitamin D deficiency. They demonstrated significant improvements in tear break-up time (TBUT), Schirmer’s test and ocular surface disease index (OSDI) scores following vitamin D supplementation[3, 4].

Building on this promising evidence, a recent clinical trial led by Hassanpour et al explored a novel approach: topical vitamin D eye drops[5].

Study Title

Safety and Efficacy of Topical Vitamin D in the Management of Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Placebo-Controlled Double-Blind Randomized Controlled Trial[5].

Q&A: Insights from the Study

Q: What was the rationale for testing topical vitamin D?
A: Given the positive ocular benefits of systemic vitamin D, this study aimed to assess whether topical administration could provide local therapeutic effects in patients with DED associated with meibomian gland dysfunction (MGD).

Q: What was the study design?
A: The study was a double-blind randomized control trial including 56 patients with both DED and MGD. They were randomly assigned to receive either vitamin D eye drops or placebo eye drops, administered in one eye four times daily for 8 weeks.

Q: What were the results?
A: At 8 weeks, the vitamin D group demonstrated statistically significant improvements across all major outcomes compared to the placebo group:

• Corneal fluorescein staining: improved ocular surface integrity
• Dry Eye Questionnaire (DEQ 5): reduced subjective symptoms of dry eyes
• Schirmer test: increased tear production
• TBUT: longer tear film breakup time
• Meibomian gland expressibility score: improved gland function
• OSDI score: reduced severity of DED

Q: Were there any adverse effects?
A: The treatment was well tolerated. There were no statistically significant ocular adverse events compared to the placebo group, and no participants discontinued the study due to side effects.

Q: Are topical vitamin D eye drops commercially available?
A: The eye drops were specifically prepared for research purposes and are not currently available on the market.

Conclusion

Topical vitamin D appears to be a safe and promising option for the treatment of DED associated with MGD. This study highlights the need for further research and development of vitamin D-based ocular therapies.

References

1.           Clayton, J.A., Dry Eye. N Engl J Med, 2018. 378(23): p. 2212-2223.

2.           Sassi, F., C. Tamone, and P. D’Amelio, Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients, 2018. 10(11).

3.           Bae, S.H., et al., Vitamin D Supplementation for Patients with Dry Eye Syndrome Refractory to Conventional Treatment. Sci Rep, 2016. 6: p. 33083.

4.           Rolando, M. and S. Barabino, Dry Eye Disease: What Is the Role of Vitamin D? Int J Mol Sci, 2023. 24(2).

5.           Hassanpour, K., et al., Safety and Efficacy of Topical Vitamin D in the Management of Dry Eye Disease Associated With Meibomian Gland Dysfunction: A Placebo-Controlled Double-Blind Randomized Controlled Trial. Cornea, 2024. 43(5): p. 552-563.

Submitted by: Felix Plamondon

The European Society of Cataract and Refractive Surgeons invites professionals around the world to participate to their 43^rd congress. The event will include many learning activities such as the main symposia, instructional courses, wetlabs, video sessions, posters and oral presentations.

Date: September 12th to 16th 2025.

Location: Bella Center Copenhagen, Center Boulevard, 2300 Copenhagen S

Important information: 

COS is now accepting abstracts and video submissions for the 2026 Annual Meeting in Montréal, Québec happening on June 18-21, 2026. The submission deadline is Friday, October 3, 2025 at 3:59 PM (EST).

What We’re Looking For: 

• Latest research findings 
• Clinical innovations 
• Best practices in ophthalmology 
• Videos featuring ophthalmic surgery, procedure, education or innovative techniques, for our inaugural COS Film Festival—an exciting new initiative to feature surgical videos, innovative techniques, and creative storytelling in ophthalmology. Be part of this first-of-its-kind celebration of visual learning and peer-to-peer education.  

Before You Submit
Please review the submission guidelines – they are important changes for 2026.  

The Canadian Ophthalmological Society (COS) Ergonomics and Injury Prevention Working Group is committed to promoting physical wellness across all stages of ophthalmology practice. Through educational initiatives, resource development, and collaborative research, we aim to make a focus on ergonomics a standard in Canadian ophthalmic care.

Our Mission: To eliminate work-related injuries for Canadian ophthalmologists.

Our Vision: To educate every Canadian ophthalmologist on ergonomics and how best to mitigate risks.

Our Values: Respect, passion, teamwork, creativity, inclusion, and diversity.

Our Current Projects:

• Canadian Handbook for Ergonomics and Injury Prevention for Ophthalmologists
• Ergonomics Toolbox for Residents
• Resident Ergonomics Curriculum Development
• Social Media Educational Initiatives and Challenges
• Sightlines Ergonomics Educational Initiatives
• SAP: Ergonomics: Doesn’t Hurt To Think About It, But It May Hurt Not To! (Royal College MOC Section 3 Accredited)
• Webinar: We’ve Got Your Back! A COS Working Group in Ergonomics and Injury Prevention Webinar (October 2025)
• Ergonomics Podcast (Fall 2025)
• And many more…!

Ergonomics and Injury Prevention Working Group Members

Journal Articles & Editorials:
Explore the growing body of peer-reviewed research on ergonomics in ophthalmology and microsurgery.
LEARN MORE →

Magazine Articles:
Hear directly from ophthalmologists about real-world experiences, preventive tips, and system-wide challenges related to MSK injury.
                LEARN MORE →

Podcasts & Videos:
Prefer to learn on the go? Explore expert-led podcasts and video content on ergonomics in ophthalmology and surgery.
LEARN MORE →

Ophthalmology Educational Series:
Engage with HIGH-YIELD accredited modules and curated training developed by national experts.
LEARN MORE →

Other Ergonomics Resources for Physicians:
Ergonomic challenges affect all healthcare providers. Learn from a broader body of literature in medicine and surgery.
LEARN MORE →

Scientific Planning Committee

Dr. Parnian Arjmand – Chair
I have a relationship with a for-profit and/or non-profit organization to diclose:

• Any direct financial payments, including receipt of honoraria: COS
• Membership on advisory boards or speakers’ bureaus: Roche, Bayer, Apobiologix

Dr. Vlad Diaconita – Member
I have a relationship with a for-profit and/or non-profit organization to disclose:

• Any direct financial payments, including receipt of honoraria: Voiant LLC Consultant
• Membership on advisory boards or speakers’ bureaus: Biogen, Roche

Dr. Bryon McKay – Member
I do not have a relationship with a for-profit and/or non-profit organization to disclose.

Dr. Miral Mehta-Shounak – Member
I do not have a relationship with a for-profit and/or non-profit organization to disclose.

The 2025 COS Annual Meeting was held from June 19th to 22nd, 2025 in the beautiful Vancouver, British Columbia. This meeting boasted an outstanding international and Canadian faculty presenting the latest in ophthalmic research and practice. The COS Annual Meeting and Exhibition included invited lectures, scientific papers, wet labs and workshops, as well as networking opportunities and an extensive exhibition of ophthalmic equipment and services.

If you registered for the Annual Meeting but did not get a chance to check out the ePoster station, you’re in luck! Our ePosters are still available for viewing. Here is how to access the platform:

• Go to: https://cos.multiregistration.com/autologin/COS2025
• Enter the email address you used when you registered for the COS 2025 Annual Meeting
• Check your inbox (or spam folder) for an email with direct access to the link. You will then have access to the 2025 COS Annual Meeting Gallery Platform.

Learning from ePosters may be claimed as Education content review (reading), under Section 2 of the MOC Program as defined by the RCPSC. You may claim 0.5 credits per hour.

Scientific Planning Committee

Dr. Parnian Arjmand – Chair
I have a relationship with a for-profit and/or non-profit organization to diclose:

• Any direct financial payments, including receipt of honoraria: COS
• Membership on advisory boards or speakers’ bureaus: Roche, Bayer, Apobiologix

Dr. Vlad Diaconita – Member
I have a relationship with a for-profit and/or non-profit organization to disclose:

• Any direct financial payments, including receipt of honoraria: Voiant LLC Consultant
• Membership on advisory boards or speakers’ bureaus: Biogen, Roche

Dr. Bryon McKay – Member
I do not have a relationship with a for-profit and/or non-profit organization to disclose.

Dr. Miral Mehta-Shounak – Member
I do not have a relationship with a for-profit and/or non-profit organization to disclose.

Speakers

Dr. Sophie Bakri
I have a relationship with a for-profit and/or non-profit organization to disclose:

• Any direct financial payments, including receipt of honoraria: Abbvie, Adverum, Allergan, Amgen, Annexon, Apellis, Aviceda, Cholgene, Eyepoint, Ilumen, Iveric Bio, Kala, Genentech, Neurotech, Novartis, Ocular Therapeutix, Outlook, Pixium, Regenxbio, Regeneron, Rejuvitas, Revana, Roche, VoxelCloud, Zeiss
• Membership on advisory boards or speakers’ bureaus: Abbvie, Adverum, Allergan, Amgen, Annexon, Apellis, Aviceda, Cholgene, Eyepoint, Ilumen, Iveric Bio, Kala, Genentech, Neurotech, Novartis, Ocular Therapeutix, Outlook, Regenxbio, Regeneron, Rejuvitas, Revana, Roche, VoxelCloud, Zeiss
• Funded grants or clinical trials: Lowy Medical Foundation, Regenxbio
• Patents on a drug, product, or device: EP4284507A1, WO2023201312A2

Dr. Michael Klufas
I have a relationship with a for-profit and/or non-profit organization to disclose:

• Any direct financial payments including receipt of honoraria: Genentech, Regeneron, DORC/Zeiss, Alimeria, Coherus, Allergan, Bayer
• Membership on advisory boards or speakers’ bureaus: RegenxBio, Biogen, Coherus, Genentech, Regeneron
• Funded grants or clinical trials: Bausch and Lomb

This webinar would not have been possible without the help of our sponsors. Thank you to Apotex, Biocon Biologics and Biogen.